15 results about "Transcription Activation" patented technology

The present application relates to a kind of FOXM1 protein phosphorylation modification interfering peptide and its application, belong to the field of biological medicine technology. Specifically, the present application is found in research, the transcriptional activity of FOXM1 protein depends on the condensate formed by its polymerization, destroying the polymerization of FOXM1 can effectively inhibit the occurrence and development of tumor, and the phosphorylation of the 376th amino acid of FOXM1 protein can also inhibit polymerization to some extent, thereby inhibiting the transcriptional activation of FOXM1 protein. Therefore, the present application designs an interfering peptide, and introduces phosphorylation modification in appropriate position, obtains a kind of phosphorylation modification interfering peptide FIP4 targeted to FOXM1 protein polymerization domain, the interfering peptide plays a significant role in inhibiting the transcriptional activation of FOXM1 protein in cell and animal in vivo, and can be used for treating tumor-related diseases.

The application belongs to the field of molecular biological technology, and particularly relates to CeABI3B a gene, an expression vector and application thereof in plant oil regulation. CeABI3B The application provides a gene for the first time, a nucleotide sequence of which is shown as SEQ ID NO. 1, and a coding region of which has a full length of 1707 bp. CeABI3B A series of vectors containing the gene are constructed for the first time, including subcellular localization, yeast hybridization and plant overexpression, and it is proved that the CeABI3B protein has a transcription activation function and is located in the cell nucleus, which is in line with the basic characteristics of transcription factors. CeABI3B Not only is it found that transient overexpression of the gene can significantly improve the oil content of tobacco leaves, but also it is proved that overexpression of the gene can significantly improve the oil content of transgenic Arabidopsis thaliana seeds and leaves. CeABI3B Therefore, the cloned and identified gene can be used to improve the oil content of plant seeds and nutrient tissues, and has a wide application prospect.

This invention belongs to the field of biomedicine and regenerative medicine technology. It discloses a chimeric polypeptide, related biomaterials, and their application in inducing cardiomyocytes. The chimeric polypeptide is obtained through family homologous domain substitution and is selected from the following groups: (1) a MEF2 chimeric polypeptide with MEF2C protein as the backbone, wherein the N-terminal and C-terminal transcriptional activation domains are replaced by homologous regions of MEF2B and MEF2D, respectively; (2) a GATA chimeric polypeptide with GATA4 protein as the backbone, wherein the N-terminal transcriptional activation domain is replaced by homologous regions of GATA1 and GATA6. This invention also provides the nucleic acid encoding the polypeptide, the construct, and a method for efficiently inducing fibroblast reprogramming into cardiomyocytes under in vitro conditions. When the chimeric polypeptide of this invention is used alone or in combination, the induced cells exhibit calcium ion oscillations earlier and have higher maturity.

The present disclosure relates to heterocyclic compounds and methods that may be useful as inhibitors of transcriptional activator proteins, such as CBP and P300, for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.

This invention relates to the field of gene editing technology, specifically to a gene circuit-based specific gene expression system and module, a pharmaceutical composition, and its applications. The system includes a first vector and a second vector. The first vector includes a first expression cassette containing a cell-specific promoter, a coding sequence encoding a transcriptionally activated fusion protein, and a regulatory region sequence downstream of the coding sequence. The regulatory region sequence is configured to form a response element in the 3' untranslated region of the fusion protein's mRNA after transcription. This response element binds to a specific long non-coding RNA within the silenced cell, leading to the degradation of the fusion protein's mRNA. The second vector includes a second expression cassette containing an associated promoter that can be activated by the transcriptionally activated fusion protein, and a target gene downstream of the associated promoter. Advantages: This ensures that the target protein is expressed only in target cells and not in cancer cells, avoiding adverse effects on non-target cells or tissues, and reducing treatment risks and side effects.

The present application relates to a VPR mutant protein capable of activating gene expression of saccharomyces cerevisiae, which is obtained by randomly mutating the commonly used activation protein VPR in saccharomyces cerevisiae, using the designed fluorescent protein and resistance gene as a screening marker, has higher transcription activation efficiency, and expands the application range of CRISPR technology in the field of gene regulation of saccharomyces cerevisiae.

Methods of inducing rejuvenation in a population of adult glial progenitor cells, and methods of treating a subject having a myelin deficiency are disclosed in this patent application. The method of inducing rejuvenation in a population of adult glial progenitor cells may comprise administering, to the population of adult glial progenitor cells, an effective amount of an agent that suppresses one or more transcription factors selected from the group consisting of (i) zinc finger protein 274 (ZNF274), (ii) Myc-associated factor X (MAX), (iii) E2F transcription factor 6 (E2F6), (iv) zinc finger protein Aiolos (IKZF3), and (v) signal transducer and activator of transcription 3 (STAT3).

This invention discloses a stable A549 expression cell line constructed based on a dCas9-VP64 transcriptional activation system and its applications. Based on the dCas9-VP64 transcriptional activation system, this invention yielded a stable A549 expression cell line with the highest relative expression level of dCas9 protein after puromycin selection. Subsequently, by introducing sgRNAs targeting one or more genes into this cell line, the expression of endogenous genes in lung cancer cells can be activated, and related functional gene studies can be conducted. Furthermore, this invention prepares an A549 cell line with significantly reduced proliferation rate by introducing sgRNA targeting the TP53 binding site in the LTR5Hs sequence into this cell line. This invention is the first to discover a novel target for lung cancer treatment, which is of great significance for the treatment and mechanistic research of lung cancer.

This invention discloses CeABI5 Genes, expression vectors, and their applications in plant oil regulation. This invention is the first to clone... CeABI5 The gene, whose coding region is 1125 bp in length, contains a conserved bZIP domain in its protein; a model was constructed. CeABI5 A series of vectors were developed for gene subcellular localization, yeast hybridization, and plant overexpression; for the first time, it was demonstrated that the CeABI5 protein has transcriptional activation function in yeast and is located in the cell nucleus, consistent with the basic characteristics of transcription factors; tobacco was transformed using Agrobacterium-mediated microinjection, demonstrating... CeABI5 Transient overexpression of the gene significantly increased the oil content in leaves; this was confirmed by transforming Arabidopsis thaliana using the inflorescence immersion method. CeABI5 Overexpression significantly increases the oil content in transgenic Arabidopsis seeds and leaves; the cloned and identified in this invention... CeABI5 Genes can be used to increase the oil content of plant seeds and vegetative tissues.

Disclosed herein are novel transcription factors for promoting reprogramming of, and / or for direct conversion of, an astrocyte to a neuron. Further provided are polynucleotides encoding the transcription factors, as well as DNA targeting composition to activate expression of the transcription factor. The DNA targeting compositions may include a Cas9 protein or fusion protein, and at least one gRNA. Further provided are methods of treating a neurodegenerative disease or neurodegenerative injury.

This invention discloses a Dutch iris IhHD12 Genes, their expressed proteins, and applications belong to the field of plant genetic engineering technology. The Dutch iris mentioned above... IhHD2 The gene, whose nucleotide sequence is shown in SEQ ID NO.1, and the amino acid sequence of the expressed protein are shown in SEQ ID NO.2. Yeast activity experiments showed that this transcription factor possesses transcriptional activation activity. Functional identification based on transgenic rice plants revealed that the transformation of Dutch iris... IhHD12 The rice plants from the genetic line exhibit a phenotype of reduced plant height. This characteristic can provide some reference for breeding new dwarf Dutch iris varieties.

This invention provides a method for controlling the immunogenicity of manipulated cells. [Solution] The method is, (a) Obtaining isolated cells, (b) To produce engineered cells by introducing into the isolated cells (i) a nucleic acid containing an inducible RNA polymerase promoter operably linked to an shRNA sequence targeting an immunosuppressive factor, and (ii) a nucleic acid containing a promoter operably linked to a transactivator element corresponding to the inducible RNA polymerase promoter, (c) Exposing the manipulated cells to an exogenous factor for activating the transactivator element, thereby controlling the immunogenicity of the manipulated cells, Includes.

This invention provides a triptolide sustained-release hydrogel targeting the FOSB and TGFB1 axes and its applications, belonging to the field of biomedical materials and drug delivery technology. The sustained-release hydrogel is a core-shell structured sequential release hydrogel. The outer layer is a 40 mg / mL low-concentration gelatin methacrylamide hydrogel loaded with stromal cell-derived factor-1α (SDF-1α), and the inner layer is a 60 mg / mL high-concentration GelMA hydrogel loaded with triptolide. This invention is the first to clearly demonstrate that the transcription factor FOSB constitutes a core driving pathway for endometriosis fibrosis by transcribing and activating TGFB1. Triptolide can directly bind to FOSB and promote its ubiquitination-mediated degradation, thereby blocking the TGF-β / Smad signaling pathway and mesenchymal-myofibroblast transformation. Through a synergistic recruitment-targeted inhibition strategy using core-shell hydrogels, SDF-1α rapidly recruits myofibroblasts in the lesion area, and tripterygium wilfordii achieves local sustained release over 14 days. While significantly inhibiting fibrosis and reducing the size of endometriosis lesions, it avoids the hepatotoxicity and off-target damage of free drugs.

This article discloses a transcription activation fusion protein, a CRISPR-Cas-based transcription activation system, and their applications in epigenetic activation. Specifically, it discloses a transcription activation fusion protein, a transcription activation fusion protein polypeptide, a CRISPR transcription activation system, and its nucleic acids, vectors, vector systems, delivery systems, cells, compositions, drugs, kits, and methods for activating the transcriptional expression of target nucleic acids using the aforementioned components.